[ad_1] Top-Line Results from 6-month double-blind Phase 2b PARADIGM trial with NeuroSense’s lead drug candidate for ALS, PrimeC, include: PrimeC achieved primary safety and tolerability endpoints with a safety and…
Tag: Clinical Trials & Medical Discoveries
NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
[ad_1] Clinical efficacy top-line results of PARADIGM, a Phase 2b trial in ALS, expected in December 2023 CAMBRIDGE, Mass., Nov. 13, 2023 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a…
Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta
[ad_1] PALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its…
Chiesi Global Rare Diseases Announces Multiple Presentations at SSIEM Annual Symposium 2023
[ad_1] – Total of six poster presentations analyze the effects of treatment with enzyme replacement therapies in Fabry disease and alpha-mannosidosis – – Company sponsoring symposium on advances in monitoring…
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
[ad_1] First Person Treated in Germany; Reimbursement Discussions on Track in France and Italy In the U.S., ROCTAVIAN Now Commercially Available and Hemophilia Treatment Centers Have Begun Screening Eligible Individuals…
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
[ad_1] PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug…
Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer
[ad_1] June 21, 2023, at The Yale Club, New York City Featured speakers and Key Opinion Leaders include: Dr Christian Behrenbruch, Dr Colin Hayward, Kevin Richardson, Dr Brian Shuch and…
Innovent Releases Final Analysis Results of ORIENT-15: the Phase 3 Study of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma at the AACR Annual Meeting 2023
[ad_1] ROCKVILLE, Md. and SUZHOU, China, April 16, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for…
THORNE HEALTHTECH SHARES RESULTS OF COLLABORATIVE CLINICAL TRIAL WITH MAYO CLINIC AND HEALTHTECH CONNEX, INC. – “THE EFFECTS OF A DIETARY SUPPLEMENT ON BRAIN FUNCTION AND STRUCTURE IN JUNIOR A ICE HOCKEY PLAYERS”
[ad_1] Significant positive findings from a double-blinded, placebo-controlled trial that measured brain function in ice hockey players over a season NEW YORK, April 4, 2023 /PRNewswire/ — Thorne HealthTech, Inc.…